This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/usa/520896-fda-pause-johnson-covid-vaccine/

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
FDA calls for ‘pause’ on Johnson & Johnson Covid vaccine after six women get blood clot disorder resulting in one death FDA calls for ‘pause’ on Johnson & Johnson Covid vaccine after six women get blood clot disorder resulting in one death
(about 1 month later)
The US Food and Drug Administration (FDA) and the CDC have called for a pause of Johnson & Johnson's Covid-19 vaccine after it reportedly caused at least one death and gave others serious blood clotting.The US Food and Drug Administration (FDA) and the CDC have called for a pause of Johnson & Johnson's Covid-19 vaccine after it reportedly caused at least one death and gave others serious blood clotting.
“We are recommending a pause in the use of this vaccine out of an abundance of caution,” declared the FDA on Tuesday, pointing toward six “extremely rare” cases of people suffering a “severe type of blood clot” after being vaccinated. Over 6.8 million Americans have received the Johnson & Johnson vaccine, with even more internationally.“We are recommending a pause in the use of this vaccine out of an abundance of caution,” declared the FDA on Tuesday, pointing toward six “extremely rare” cases of people suffering a “severe type of blood clot” after being vaccinated. Over 6.8 million Americans have received the Johnson & Johnson vaccine, with even more internationally.
Revealing that the Centers for Disease Control and Prevention (CDC) “will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance,” the FDA added in its statement that until the investigation is complete, it is “recommending this pause” of Johnson & Johnson's vaccine.Revealing that the Centers for Disease Control and Prevention (CDC) “will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance,” the FDA added in its statement that until the investigation is complete, it is “recommending this pause” of Johnson & Johnson's vaccine.
The six affected people were all women between the ages of 18 and 48 who developed the condition between six and 13 days of vaccination, the statement says.The six affected people were all women between the ages of 18 and 48 who developed the condition between six and 13 days of vaccination, the statement says.
Professor Sabra Klein, the co-Director of the Johns Hopkins Center for Women's Health, Sex, and Gender Research, responded to the news by questioning when the FDA and the CDC would "start requiring partitioning and analyzing clinical trials by biological sex" to determine vaccine effects on women.Professor Sabra Klein, the co-Director of the Johns Hopkins Center for Women's Health, Sex, and Gender Research, responded to the news by questioning when the FDA and the CDC would "start requiring partitioning and analyzing clinical trials by biological sex" to determine vaccine effects on women.
Last week, the European Medicines Agency announced an investigation into Johnson & Johnson's vaccine and its potential links to blood clotting.Last week, the European Medicines Agency announced an investigation into Johnson & Johnson's vaccine and its potential links to blood clotting.
The AstraZeneca Covid-19 vaccine is also being investigated over blood clot cases, and several countries have advised against using the vaccine on young recipients.The AstraZeneca Covid-19 vaccine is also being investigated over blood clot cases, and several countries have advised against using the vaccine on young recipients.
Think your friends would be interested? Share this story!Think your friends would be interested? Share this story!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.